These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 9707208

  • 1. Effects of a synthetic allosteric modifier of hemoglobin oxygen affinity on outcome from global cerebral ischemia in the rat.
    Grocott HP, Bart RD, Sheng H, Miura Y, Steffen R, Pearlstein RD, Warner DS.
    Stroke; 1998 Aug; 29(8):1650-5. PubMed ID: 9707208
    [Abstract] [Full Text] [Related]

  • 2. Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat.
    Sarraf-Yazdi S, Sheng H, Grocott HP, Bart RD, Pearlstein RD, Steffen RP, Warner DS.
    Brain Res; 1999 May 01; 826(2):172-80. PubMed ID: 10224294
    [Abstract] [Full Text] [Related]

  • 3. RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass.
    Kilgore KS, Shwartz CF, Gallagher MA, Steffen RP, Mosca RS, Bolling SF.
    Circulation; 1999 Nov 09; 100(19 Suppl):II351-6. PubMed ID: 10567328
    [Abstract] [Full Text] [Related]

  • 4. Effects of a pharmacologically-induced shift of hemoglobin-oxygen dissociation on myocardial energetics during ischemia in patients with coronary artery disease.
    Najjar SS, Bottomley PA, Schulman SP, Waldron MM, Steffen RP, Gerstenblith G, Weiss RG.
    J Cardiovasc Magn Reson; 2005 Nov 09; 7(4):657-66. PubMed ID: 16136855
    [Abstract] [Full Text] [Related]

  • 5. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs.
    Pagel PS, Hettrick DA, Montgomery MW, Kersten JR, Steffen RP, Warltier DC.
    J Pharmacol Exp Ther; 1998 Apr 09; 285(1):1-8. PubMed ID: 9535987
    [Abstract] [Full Text] [Related]

  • 6. Reducing hemoglobin oxygen affinity does not increase hydroxyl radicals after acute subdural hematoma in the rat.
    Doppenberg EM, Rice MR, Alessandri B, Qian Y, Di X, Bullock R.
    J Neurotrauma; 1999 Feb 09; 16(2):123-33. PubMed ID: 10098957
    [Abstract] [Full Text] [Related]

  • 7. Allosteric modification of oxygen delivery by hemoglobin.
    Wahr JA, Gerber M, Venitz J, Baliga N.
    Anesth Analg; 2001 Mar 09; 92(3):615-20. PubMed ID: 11226087
    [Abstract] [Full Text] [Related]

  • 8. The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats.
    Grinberg OY, Miyake M, Hou H, Steffen RP, Swartz HM.
    Adv Exp Med Biol; 2003 Mar 09; 530():287-96. PubMed ID: 14562725
    [Abstract] [Full Text] [Related]

  • 9. Post-ischemic RSR13 amplifies the effect of dizocilpine on outcome from transient focal cerebral ischemia in the rat.
    Mackensen GB, Nellgård B, Sarraf-Yazdi S, Dexter F, Steffen RP, Grocott HP, Warner DS.
    Brain Res; 2000 Jan 17; 853(1):15-21. PubMed ID: 10627303
    [Abstract] [Full Text] [Related]

  • 10. The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats.
    Miyake M, Grinberg OY, Hou H, Steffen RP, Elkadi H, Swartz HM.
    Adv Exp Med Biol; 2003 Jan 17; 530():319-29. PubMed ID: 14562728
    [Abstract] [Full Text] [Related]

  • 11. Right-shifting the oxyhemoglobin dissociation curve with RSR13: effects on high-energy phosphates and myocardial recovery after low-flow ischemia.
    Woods JA, Storey CJ, Babcock EE, Malloy CR.
    J Cardiovasc Pharmacol; 1998 Mar 17; 31(3):359-63. PubMed ID: 9514179
    [Abstract] [Full Text] [Related]

  • 12. Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity.
    Weiss RG, Mejia MA, Kass DA, DiPaula AF, Becker LC, Gerstenblith G, Chacko VP.
    J Clin Invest; 1999 Mar 17; 103(5):739-46. PubMed ID: 10074492
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
    Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, Ruffer J, Gerber M.
    J Clin Oncol; 1999 Aug 17; 17(8):2593-603. PubMed ID: 10561327
    [Abstract] [Full Text] [Related]

  • 14. Effect of RSR13 on temperature-dependent changes in hemoglobin oxygen affinity of human whole blood.
    Steffen RP.
    Adv Exp Med Biol; 1998 Aug 17; 454():653-61. PubMed ID: 9889946
    [No Abstract] [Full Text] [Related]

  • 15. Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.
    Eichelbrönner O, D'Almeida M, Sielenkämper A, Sibbald WJ, Chin-Yee IH.
    Am J Physiol Heart Circ Physiol; 2002 Jul 17; 283(1):H92-101. PubMed ID: 12063279
    [Abstract] [Full Text] [Related]

  • 16. Effects of enhanced oxygen release from hemoglobin by RSR13 in an acute renal failure model.
    Burke TJ, Malhotra D, Shapiro JI.
    Kidney Int; 2001 Oct 17; 60(4):1407-14. PubMed ID: 11576354
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.
    Wainwright MS, Sheng H, Sato Y, Mackensen GB, Steffen RP, Pearlstein RD, Warner DS.
    Am J Physiol Heart Circ Physiol; 2002 May 17; 282(5):H1863-70. PubMed ID: 11959653
    [Abstract] [Full Text] [Related]

  • 18. The rationale for, and effects of oxygen delivery enhancement to ischemic brain in a feline model of human stroke.
    Doppenberg EM, Watson JC, Bullock R, Gerber MJ, Zauner A, Abraham DJ.
    Ann N Y Acad Sci; 1997 Oct 15; 825():241-57. PubMed ID: 9369991
    [Abstract] [Full Text] [Related]

  • 19. The effects of RSR13 on microvascular Po2 kinetics and muscle contractile performance in the rat arterial ligation model of peripheral arterial disease.
    Watanabe A, Poole DC, Kano Y.
    J Appl Physiol (1985); 2017 Oct 01; 123(4):764-772. PubMed ID: 28620055
    [Abstract] [Full Text] [Related]

  • 20. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
    Rockwell S, Kelley M.
    Radiat Oncol Investig; 1998 Oct 01; 6(5):199-208. PubMed ID: 9822166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.